Table 1.
Clinical and biochemical features of the study patients (column “ALL”) and comparison between women in premenopausal status (PRE) and postmenopausal status (POST) at the time of CBG withdrawal
| Group | ALL | PRE | POST | p value (PRE vs. POST) |
|---|---|---|---|---|
| Age at diagnosis, median (range) (years) | 29 (15–53) | 28 (15–43) | 43 (24–53) | < 0.001 |
| Maximum diameter, mean ± SD (mm) | 5.7 ± 1.6 | 5.6 ± 1.6 | 6.3 ± 1.7 | ns |
| PRL at diagnosis, median (range) (mIU/L) | 2056 (933–4537) | 2014 (933–4537) | 2120 (1102–4070) | ns |
| Other dopamine agonists prior to CBG (n) | 21/62a | 16/48 | 5/14 | ns |
| Treatment duration, median (range) (years) | 3 (1–25) | 3 (1–11) | 5 (2–25) | 0.001 |
| CBG dose per week, median (range) (mg) | 0.5 (0.25–1.5) | 0.5 (0.25–1.5) | 0.5 (0.25–1) | ns |
| Cumulative CBG dose, median (range) (mg) | 78 (13–1300) | 52 (13–390) | 130 (52–1300) | 0.007 |
| Age at withdrawal, median (range) (years) | 34 (20–56) | 31 (20–49) | 51 (46–56) | < 0.001 |
| PRL before withdrawal, median (range) (mIU/L) | 161 (21–464) | 148 (21–464) | 165 (42–403) | ns |
| Prolactinoma disappearance before withdrawal (n) | 19/62 | 14/48 | 5/14 | ns |
aSixteen treated with bromocriptine, 1 with lysuride, 2 with dihydroergocryptine, 1 with quinagolide, and 1 with dihydroergocryptine followed by bromocriptine
PRL, prolactin levels; CBG, cabergoline